SCHEMBL557352

SCHEMBL557352

Clc1ccn2ccnc2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN2 Q96KS0 1/20 0.39
PIK3C3 Q8NEB9 1/20 0.38
F10 P00742 1/20 0.36
DYRK1A Q13627 2/20 0.36
KEAP1 Q14145 1/20 0.36
KMT2A Q03164 2/20 0.35
P2RX3 P56373 1/20 0.34
P2RX2 Q9UBL9 1/20 0.34
MEN1 O00255 1/20 0.34
CYP1A2 P05177 1/20 0.34
TGFBR1 P36897 2/20 0.34
MAOB P27338 1/20 0.34
QPCT Q16769 1/20 0.34
PIK3CD O00329 1/20 0.34
ABL1 P00519 1/20 0.34
EGFR P00533 1/20 0.34
HCK P08631 1/20 0.34
SRC P12931 1/20 0.34
KDR P35968 1/20 0.34
PIK3CA P42336 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21364619 0.79 PIK3C3 (0.46) PIK3C3DYRK1ATGFBR1QPCTPIK3CD
SCHEMBL174229 0.74 DYRK1A (0.43) PIK3C3DYRK1AKEAP1KMT2AMEN1
SCHEMBL11026 0.74 L3MBTL1 (0.40) PIK3C3DYRK1AKEAP1KMT2AMEN1
SCHEMBL17868755 0.74 PIK3C3 (0.38) PIK3C3DYRK1AKEAP1KMT2AMEN1
SCHEMBL601353 0.74 PIK3C3 (0.41) PIK3C3DYRK1AKEAP1KMT2AMEN1
SCHEMBL3185174 0.74 PIK3C3 (0.38) PIK3C3DYRK1AKEAP1KMT2AMEN1
SCHEMBL14144231 0.74 PIK3C3 (0.38) PIK3C3DYRK1AKEAP1KMT2AMEN1
SCHEMBL20755769 0.74 PIK3C3 (0.38) PIK3C3DYRK1AKEAP1KMT2AMEN1
SCHEMBL18554370 0.74 OGA (0.39) PIK3C3DYRK1AKEAP1KMT2AMEN1
SCHEMBL557143 0.74 SMN1; SMN2 (0.44) PIK3C3KEAP1KMT2ACYP1A2TGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 224 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119350428-B Respiratory system medicine synergist based on pyruvate and preparation method and application thereof 江苏长泰药业股份有限公司 2025-03-28 CN claimed
CN-119350428-A Respiratory system medicine synergist based on pyruvate and preparation method and application thereof 江苏长泰药业股份有限公司 2025-01-24 CN claimed
CN-112409354-B Synthesis process of 7-fluoroimidazo [1,2-A ] pyridine and intermediate thereof 苏利制药科技江阴有限公司 2021-10-08 CN claimed
CN-112409354-A Synthesis process of 7-fluoroimidazo [1,2-A ] pyridine and intermediate thereof 苏利制药科技江阴有限公司 2021-02-26 CN claimed
EP-3340982-A1 COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS Achillion Pharmaceuticals, Inc. (US) 2018-07-04 EP claimed
WO-2017035408-A1 COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2017-03-02 WO claimed
EP-4688777-A1 NOVEL PD-L1 INHIBITORS Affirma Biotech S. L. (ES) 2026-02-11 EP disclosed
US-12391679-B2 Benzamide-substituted bicyclic imidazo- and pyrazolo-fused -pyridine, -pyrimide, and -pyridazine compounds for treatment of inflammatory diseases ONCO3R THERAPEUTICS BV (BE) 2025-08-19 US disclosed
US-12338230-B2 Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders ACHILLION PHARMACEUTICALS, INC. (US) 2025-06-24 US disclosed
CN-119350428-B Respiratory system medicine synergist based on pyruvate and preparation method and application thereof 江苏长泰药业股份有限公司 2025-03-28 CN disclosed
CN-119350428-B Respiratory system medicine synergist based on pyruvate and preparation method and application thereof 江苏长泰药业股份有限公司 2025-03-28 CN disclosed
WO-2025038525-A1 FMS-LIKE TYROSINE KINASE 3 (FLT3) INHIBITORS FOR TREATING CELL PROLIFERATIVE DISEASES OR CONDITIONS BIOVENTURES, LLC (US) 2025-02-20 WO disclosed
CN-119350428-A Respiratory system medicine synergist based on pyruvate and preparation method and application thereof 江苏长泰药业股份有限公司 2025-01-24 CN disclosed
WO-2001038326-A2 IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 2001-05-31 WO disclosed
US-4163745-A ANTIDIABETIC, HYPOGLYCEMIC PFIZER INC. (US) 1979-08-07 US disclosed
US-4141898-A Imidazo pyridinium quaternary salts as hypoglycemic agents PFIZER INC. (US) 1979-02-27 US disclosed
US-4129567-A IMIDAZOPYRIDINES AND ISOB IDINE PFIZER INC. (US) 1978-12-12 US disclosed
US-4097598-A Quaternary salts as hypoglycemic agents PFIZER INC. (US) 1978-06-27 US disclosed
US-4093616-A PYRROLO(1,2-A)PYRAZINIUM, PYRAZOLO(1,5-A)PYRIDINIUM, 1H-IMIDAZO(2,1-A)ISOQUINOLINIUM, OR IMIDAZO(5,1-A)ISOQUINOLINIUM SALTS PFIZER INC. (US) 1978-06-06 US disclosed
US-4044015-A Imidazopyridinium compounds as hypoglycemic agents PFIZER INC. (US) 1977-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12338230-B2 Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders CFD, TFPI, CFH EGLN2 995/4885PIK3C3 225/4885F10 50/4885
US-12391679-B2 Benzamide-substituted bicyclic imidazo- and pyrazolo-fused -pyridine, -pyrimide, and -pyridazine compounds for treatment of inflammatory diseases IL5, IL15, IL1A EGLN2 1189/4885PIK3C3 419/4885F10 222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.